The Results section: confusion, drowsiness key, sedation, dizziness, drowsiness, fatigue, insomnia, dizziness, participants high throughput chemical screening who have no dementia at baseline, and the test was available in English. Translation of clinical trials in other language and be able was published, was not checking for these meters possible. No sample size Enbeschr Imposed restriction. Studies that were published in duplicate were used only once. Only original studies were included. The analysis of pooled data from other clinical studies have not been used. Where data from post hoc analyzes were by big s clinical studies, a set of data was extracted by attempting to avoid duplication in subsequent analyzes. Data extraction and quality Tsbewertung two authors independently Of one another F rderf Ability of each publication for the systematic overview work and meta-analysis by filling out a data extraction determined list of criteria for the F Rderf Ability and the quality of t of the studies evaluation. A third reviewer clarified any discrepancies Rt. The studies were included in the systematic check if she reported the eligibility criteria above and the data on the person or group, randomized, open, comparative, placebo-controlled extension or after the study met. For meta-analysis only data from randomized, double-blind, controlled studies have been won Placebo strips. The age of participants was asked to consider Bicalutamide Calutide whether a separate article could be conducted for adults aged 65 years. The check in accordance with PRISMA guidelines.15 statistical analysis for the systematic verification was conducted descriptive statistics were used to measured the number of trials, the reported results or central nervous system or data stratified by the calculation of age. Experiments, the results of the central nervous system to document reported that the H FREQUENCY of undesirable CNS effects exposed by humans for each of the seven antimuscarinic was applied to the H FREQUENCY of side effects of the CNS Hnlichen individuals who don reported ‘, in comparison were not exposed to any of these agents, usually include the participants in the placebo arm of this study. The results are expressed as the rate of occurrence of pooling the results of a central nervous system in the eight cohorts were treated with placebo and those who again Oivent all seven antimuscarinic presented. A meta-analysis were performed using the full version of meta-analysis 2 Binary results of central nervous Sen side effects were calculated as odds ratios with confidence intervals of 95% for all formulations and doses of each agent. Formulations and doses in the primary meta-analysis was oral oxybutynin 2.5, 5, 9, 10, and 15 mg / day, transdermal oxybutynin 1.3, 2.6 and 3.9mg / d, oxybutynin topical gel 1 mg / d, intravesical oxybutynin 20 mg / 40 ml, tolterodine 1, 2, 4 and 8 mg / day, fesoterodine 4, 8, 12 mg / d, propiverine 30, 45 mg / day, solifenacin 5, 10 mg / day, darifenacin 7.5, 15, 30 mg / day, trospium chloride and 40, 60 mg / day. Sub-analyzes were also to formulations containing zinc Performed Gerter release, controlled release Lee, the dose and administration of each agent routeof if more than one study was available. Meta m Possible for all CNS effects with only oral formulations of oxybutynin, all effects on the central nervous system of 15 mg oral oxybutynin IR / d only, dizzy from all the formulations of oxybutynin, the fraud, with only oral formulations of oxybutynin, dizziness with oral oxybutynin IR 15 mg / d analysis were only dizziness.